US Patent No: 7,214,665

Number of patents in Portfolio can not be more than 2000

2-propynyl adenosine analogs having A.sub.2A agonist activity and compositions thereof

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides compounds having the following general formula (I): ##STR00001## wherein X, R.sup.1, R.sup.2, R.sup.7 and Z are as described here.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
UNIVERSITY OF VIRGINIACHARLOTTESVILLE, VA322

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Figler, Robert Alan Earlysville, VA 10 126
Linden, Joel M Charlottesville, VA 36 679
Macdonald, Timothy L Charlottesville, VA 60 435
Murphree, Lauren Jean Earlysville, VA 3 36
Rieger, Jayson M Charlottesville, VA 49 498
Sullivan, Gail W Charlottesville, VA 26 623

Cited Art Landscape

Patent Info (Count) # Cites Year
 
NOVARTIS CORPORATION (1)
4,968,697 2-substituted adenosine 5'-carboxamides as antihypertensive agents 55 1989
 
AMERICAN HOME PRODUCTS CORPORATION (1)
5,124,455 Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents 75 1990
 
UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION, THE, THE TOWERS OFFICE BUILDING, SUITE 6211, 1224 W. MAIN STREET, CHARLOTTESVILLE, VA 22903 A CORP OF VA (1)
5,096,906 Method of inhibiting the activity of leukocyte derived cytokines 80 1990
 
MERCK FROSST CANADA LTD. (2)
6,020,339 Aryl furan derivatives as PDE IV inhibitors 40 1998
6,034,089 Aryl thiophene derivatives as PDE IV inhibitors 36 1998
 
UNIVERSITY OF ROCHESTER, ROCHESTER, NEW YORK 14627, A NOT-FOR-PROFIT CORP. OF NEW YORK (1)
4,938,949 Treatment of damaged bone marrow and dosage units therefor 273 1988
 
SCHERING CORPORATION (1)
5,593,975 Adenosine derivatives having A.sub.2 agonist activity 58 1995
 
BIC CORPORATION (1)
6,332,771 Utility lighter 13 1999
 
TOA EIYO LTD. (1)
* 6,936,596 Adenosine derivatives and use thereof 13 2001
 
PFIZER INC. (5)
6,326,359 Adenosine A2A receptor agonists as antiinflammatory agents 27 1999
6,350,735 Purine derivatives 15 2000
6,525,032 Purine derivatives 22 2001
6,624,158 Purine derivatives 14 2001
2003/0013,675 Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases 25 2002
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (2)
5,298,508 Irreversible inhibitors of adenosine receptors 33 1992
6,545,002 Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors 27 2000
 
PUREF, LLC (1)
6,004,945 Use of adenosine compounds to relieve pain 27 1995
 
BIOCHEM PHARMA INC. (2)
5,756,706 Processes for the diastereoselective synthesis of nucleoside analogues 46 1994
5,696,254 Processes for the diastereoselective synthesis of nucleoside analogues 47 1994
 
GLAXO WELLCOME INC. (1)
5,776,940 Phenylxanthine derivatives 27 1997
 
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (1)
5,668,139 A1 adenosine receptor agonists and antagonists 22 1995
 
NEW YORK UNIVERSITY (2)
5,932,558 Adenosine receptor agonists for the promotion of wound healing 29 1996
6,020,321 Adenosine receptor agonists for the promotion of wound healing 25 1999
 
The University of Patent Foundation (1)
5,854,081 Stable expression of human A.sub.2B adenosine receptors, and assays employing the same 37 1996
 
UNIVERSITY OF VIRGINIA (12)
5,272,153 Method of inhibiting the activity of leukocyte derived cytokines 42 1992
5,877,180 Method for treating inflammatory diseases with A.sub.2a adenosine receptor agonists 68 1994
6,117,878 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors 59 1998
6,303,619 Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors 29 1998
6,060,481 Method for improving insulin sensitivity using an adenosine receptor antagonist 26 1999
6,322,771 Induction of pharmacological stress with adenosine receptor agonists 43 1999
6,448,235 Method for treating restenosis with A2A adenosine receptor agonists 40 2000
6,514,949 Method compositions for treating the inflammatory response 38 2000
6,531,457 Methods and compositions for treating inflammatory response 27 2001
6,670,334 Method and compositions for treating the inflammatory response 31 2002
2006/0040,888 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity 12 2005
2006/0040,889 2-polycyclic propynyl adenosine analogs having A2A agonist activity 15 2005
 
UNIVERSITY OF VIRGINIA, A CORP. OF DE (1)
4,965,271 Method of inhibiting the activity of leukocyte derived cytokines 74 1987
 
ADERIS PHARMACEUTICALS, INC. (4)
5,140,015 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents 49 1990
5,278,150 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions 40 1992
RE36494 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents 23 1993
6,339,072 Compositions and methods for preventing restenosis following revascularization procedures 20 2001
 
ICOS CORPORATION (1)
5,665,754 Substituted pyrrolidines 50 1993
 
BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (1)
4,665,074 6-(polyfluoroalkoxyphenyl) pyridazinones, their compositions, synthesis and use 29 1985
 
CARDIOKINE, INC. (1)
5,998,386 Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue 44 1997
 
PATENT FOUNDATION, VIRGINIA, UNIVERSITY OF (1)
6,232,297 Methods and compositions for treating inflammatory response 29 1999
 
Item Development (1)
5,731,296 Selective vasodilation by continuous adenosine infusion 39 1993
 
AVENTIS PHARMACEUTICALS PRODUCTS INC. (2)
5,364,862 Compounds having antihypertensive and anti-ischemic properties 69 1992
5,561,134 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties 59 1994
 
PHARMACIA & UPJOHN S.P.A. (1)
5,593,976 New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds 16 1995
 
YAMASA CORPORATION (1)
* 6,387,889 Medicinal compositions for treating eye diseases 19 2001
 
BURROUGHS WELLCOME CO. (1)
4,879,296 Xanthine derivatives 50 1986
 
ANGELLO, PAUL S., 1858 PALISADES TERRACE DRIVE, LAKE OSWEGO, OREGON 97034 (1)
4,824,660 Method of determining the viability of tissue in an organism 33 1985
 
King Pharmaceuticals Research and Development, Inc. (1)
5,070,877 Novel method of myocardial imaging 69 1989
 
Yamasa Shoyu Kabushiki Kaisha (2)
4,956,345 2-alkynyladenosines as antihypertensive agents 58 1988
5,189,027 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases 56 1991
 
TEVA PHARMACEUTICAL INDUSTRIES LTD. (1)
5,565,462 Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative 26 1994
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
TROVIS PHARMACEUTICALS, LLC (6)
8,293,720 R agonists 1 2008
* 2009/0162,292 SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS 9 2008
7,888,329 R agonists 6 2009
* 8,263,762 R agonists 1 2010
* 2011/0003,766 ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A2AR AGONISTS 0 2010
* 8,222,228 Substituted aryl piperidinylalkynyladenosines as A2AR agonists 0 2010
 
UNIVERSITY OF VIRGINIA (21)
* 2009/0170,803 ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES 6 2003
7,427,606 Method to reduce inflammatory response in transplanted tissue 11 2004
* 2005/0182,018 Method to reduce inflammatory response in transplanted tissue 0 2004
* 7,605,143 agonist activity 10 2005
7,576,069 2-polycyclic propynyl adenosine analogs having A2A agonist activity 13 2005
7,442,687 2-polycyclic propynyl adenosine analogs having A2A agonist activity 7 2005
* 2006/0040,889 2-polycyclic propynyl adenosine analogs having A2A agonist activity 15 2005
* 2006/0040,888 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity 12 2005
7,378,400 Method to reduce an inflammatory response from arthritis 13 2005
* 2006/0100,169 Method to reduce an inflammatory response from arthritis 0 2005
8,178,509 Method to treat sickle cell disease 0 2007
7,737,127 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof 5 2007
* 2007/0232,559 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF 9 2007
* 2007/0265,440 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE 6 2007
8,188,063 modulators to treat spinal cord injury 2 2007
* 2008/0064,653 USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY 11 2007
7,989,431 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity 3 2009
7,875,595 2-polycyclic propynyl adenosine analogs having A2A agonist activity 4 2009
8,158,604 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof 0 2010
* 2010/0152,127 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF 4 2010
* 2011/0136,755 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY 3 2011
 
Lewis and Clark Pharmaceuticals, LLC (1)
9,067,963 A agonists 0 2013
 
ZALICUS INC. (2)
* 2009/0047,243 COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS 0 2008
* 2010/0009,934 BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS 2 2009
 
University of Virginia Patent Foundation and Adenosine Therapeutics, L.L.C. (1)
* 2009/0253,647 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY 6 2009
 
GLAXO GROUP LIMITED (2)
* 7,985,740 Purine derivatives as agonists of the adenosine A2A receptor 0 2006
* 2008/0214,581 Purine Derivatives as Agonists of the Adenosine A2a Receptor 12 2006
 
AKITA UNIVERSITY SCHOOL OF MEDICINE (1)
* 2008/0027,022 METHOD TO TREAT GASTRIC LESIONS 18 2007
 
PGXHEALTH, LLC (1)
8,058,259 R agonists 4 2008
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 8, 2018
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00